In this episode, Global Trac Solutions, Inc. CEO, David Flores, has the very distinct pleasure of being joined by Carlos Tanner, founder of the Ayahuasca Foundation in Iquitos, Peru.
Similar Posts
Spotlight on Cannara Biotech with Nicholas Sosiak
In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company’s future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn
In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.
In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.
From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.
Perhaps, psychedelics can treat mental health issues in general.
Perhaps, ketamine can be used to heal.
In the conversation, MDMA to treat addiction was also discussed.
Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.
With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.
From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.
#Psychedelics #Awakn #PsychedelicStocks
Psychedelic Spotlight Interview with James Hallifax
In this episode of the Psychedelic Spotlight podcast, we feature…
Mendeleyev: Music, Magic, Mushrooms
In the realm where music meets the mystical, few artists embody the fusion of psychedelic exploration and sonic innovation like Mendeleyev.
Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
Interview With Anthony Tennyson
We speak with Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.